Unum Therapeutics’ (UMRX) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Unum Therapeutics (NASDAQ:UMRX) in a research report report published on Tuesday morning. They currently have a $18.00 target price on the stock. Wedbush also issued estimates for Unum Therapeutics’ Q2 2018 earnings at ($0.35) EPS, Q3 2018 earnings at ($0.38) EPS, Q4 2018 earnings at ($0.41) EPS, FY2018 earnings at ($1.79) EPS, Q1 2019 earnings at ($0.31) EPS, Q2 2019 earnings at ($0.35) EPS, Q3 2019 earnings at ($0.38) EPS, Q4 2019 earnings at ($0.41) EPS, FY2019 earnings at ($1.45) EPS, FY2020 earnings at ($1.61) EPS, FY2021 earnings at ($2.28) EPS and FY2022 earnings at ($1.35) EPS.

UMRX has been the topic of several other reports. Cowen assumed coverage on Unum Therapeutics in a research note on Monday, April 23rd. They issued a market perform rating on the stock. SunTrust Banks assumed coverage on Unum Therapeutics in a research note on Monday, April 23rd. They issued a buy rating and a $21.00 price target on the stock. Finally, Morgan Stanley assumed coverage on Unum Therapeutics in a research note on Monday, April 23rd. They issued an overweight rating and a $20.00 price target on the stock.

Unum Therapeutics opened at $11.68 on Tuesday, according to Marketbeat Ratings. Unum Therapeutics has a 52-week low of $11.00 and a 52-week high of $11.36.

Unum Therapeutics (NASDAQ:UMRX) last issued its quarterly earnings results on Monday, May 14th. The company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.31). The company had revenue of $2.22 million during the quarter, compared to the consensus estimate of $2.45 million. analysts predict that Unum Therapeutics will post -1.51 earnings per share for the current year.

In other news, major shareholder Venture Fund Ix L.P. Atlas purchased 94,052 shares of Unum Therapeutics stock in a transaction that occurred on Tuesday, April 3rd. The shares were bought at an average cost of $12.00 per share, with a total value of $1,128,624.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Liam Ratcliffe purchased 550,000 shares of Unum Therapeutics stock in a transaction that occurred on Tuesday, April 3rd. The stock was purchased at an average cost of $12.00 per share, for a total transaction of $6,600,000.00. The disclosure for this purchase can be found here.

Hedge funds have recently modified their holdings of the stock. Wasatch Advisors Inc. bought a new stake in Unum Therapeutics in the first quarter worth $2,823,000. Atlas Venture Associates IX LLC bought a new stake in Unum Therapeutics in the first quarter worth $37,347,000. Dean Capital Investments Management LLC bought a new stake in Unum Therapeutics in the first quarter worth $395,000. Millennium Management LLC bought a new stake in Unum Therapeutics in the first quarter worth $982,000. Finally, Point72 Asset Management L.P. bought a new stake in Unum Therapeutics in the first quarter worth $3,599,000. 16.21% of the stock is currently owned by institutional investors.

About Unum Therapeutics

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply